BIOA vs SEPN
BIOA: Clinical-stage biotech targeting aging biology to develop novel small-molecule therapeutics for metabolic and cardiovascular diseases, led by brain-penetrant NLRP3 inhibitor BGE-102. SEPN: An early-stage biotech company developing cell receptor-targeted therapeutics for inflammation, metabolism, and other diseases through its proprietary chemistry platform.
Side-by-side fundamentals
| Metric | BIOA | SEPN | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $24.85 | $35.18 | |
| Market cap as of 2026-07-31 | $986M | $1.6B | |
| PEG as of 2026-07-31 | -0.50 | n/a | |
| Net margin as of 2026-07-31 | -871.8% | -49.9% | SEPN higher |
| Operating margin as of 2026-07-31 | -985.9% | -77.1% | SEPN higher |
| ROE as of 2026-07-31 | -29.4% | -9.4% | SEPN higher |
| ROA as of 2026-07-31 | -27.3% | -6.6% | SEPN higher |
| Debt / equity as of 2026-07-31 | 0.00 | 0.00 | SEPN lower |
| Revenue growth (YoY) as of 2026-07-31 | +91.0% | +11790.1% | SEPN higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +1644.5% | |
| Beta as of 2026-07-31 | 0.96 | 1.25 | |
| 1-year return as of 2026-07-30 close | +462.2% | +178.3% | BIOA higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.